论文部分内容阅读
[目的]探讨多药耐药基因1(multidrug resistance gene 1,MDR1)C1236T及C3435T单核苷酸多态性(SNP)与肝细胞肝癌(HCC)预后间关系。[方法]以36例HCC根治术患者为对象,同时建立50例对照组,PCR-SSCP法检测其静脉血标本C1236T及C3435T SNP,比较分析C1236T及C3435T SNP与HCC预后的关系。[结果]HCC组与对照组的基因分布无统计学差异(P>0.05)。C3435T基因型CC、CT、TT型中位无瘤生存时间依次为164.5d、340.0d和369.5d,C1236T基因型CC、CT、TT型中位无瘤生存时间依次为201.0d、415.0d、260.0d,MDR1基因多态性与HCC复发相关。[结论]C3435T SNP可作为肝癌根治术的预后因素之一。
[Objective] To explore the relationship between the multidrug resistance gene 1 (MDR1) C1236T and C3435T single nucleotide polymorphisms (SNP) and the prognosis of hepatocellular carcinoma (HCC). [Methods] Thirty-six patients with HCC underwent radical resection. Fifty control subjects were also established. The C1236T and C3435T SNPs were detected by PCR-SSCP and the relationship between C1236T and C3435T SNPs and the prognosis of HCC were analyzed. [Results] There was no significant difference in gene distribution between HCC group and control group (P> 0.05). The median tumor-free survival time of C3435T genotypes CC, CT and TT were 164.5d, 340.0d and 369.5d, respectively. The median tumor-free survival time of C1236T genotypes CC, CT and TT were 201.0d, 415.0d and 260.0 d, MDR1 gene polymorphisms associated with recurrence of HCC. [Conclusion] C3435T SNP can be used as one of the prognostic factors in radical resection of liver cancer.